ABSTRACT
We hypothesize that patterns of sexual behaviour play a role in the conformation of transmission networks. If that was the case, behavioural grouping might in turn correlate with transmission networks and have the potential to predict proximity in viral phylogenies. To address this hypothesis, we present an intuitive approach for quantifying interactions between clusters of sexual behaviour along a virus phylogeny. Data from the Swiss HIV Cohort Study on condom use and incident Hepatitis C virus (HCV) sequences served as proof-of-concept. A strict inclusion criteria contrasting with relatively low HCV prevalence hindered our ability to identify significant relationships. This manuscript intends to serve as guide for studies aimed at characterizing interactions between behavioural patterns and transmission networks. Large transmission networks such as those of HIV or COVID-19 are prime candidates for applying this methodological approach.
Competing Interest Statement
L.S.V. K.K. D.N. and A.C. do not report competing interests. H. F. G. has received unrestricted research grants from Gilead Sciences Roche a grant from Systems X grants from SHCS research foundation National Institutes of Health Yvonne Jacob Foundation personal fees from Data Safety Monitoring Board and consulting for Merck Gilead Teva and Sandoz outside the submitted work. A. R. reports support for advisory boards and/or travel grants from Janssen-Cilag Merck Sharp & Dohme (MSD) Gilead Sciences Abbvie and Bristol-Myers Squibb and an unrestricted research grant from Gilead Sciences. All remuneration went to his home institution and not to A. R. personally. D. L. B. reports support for advisory boards and/or travel grants from MSD ViiV and Gilead Sciences. R. D. K. reports personal fees from Gilead Sciences. G. W. reports grants from Gilead Sciences and AbbVie. K. E. A. D. reports contributions to her home institution from Gilead Sciences and grants from Merck Sharp and Dohme. E. B. reports payments to his home institution from Gilead Sciences MSD ViiV Healthcare Pfizer and Sandoz and grants from Gilead Sciences MSD ViiV and Pfizer J.B. is a member of the Federal Commission for Issues relating to Sexually Transmitted Infections (CFIST) K.J.M. has received travel grants and honoraria from Gilead Sciences Roche Diagnostics GlaxoSmithKline Merck Sharp & Dohme Bristol-Myers Squibb ViiV and Abbott and the University of Zurich received research grants from Gilead Science Roche and Merck Sharp & Dohme for studies that Dr Metzner serves as principal investigator and advisory board honoraria from Gilead Sciences. All these relationships were outside this work.
Funding Statement
This work was performed within the framework of the SHCS supported by the Swiss National Science Foundation (SNSF grants 177499 and 324730_179567) and by the SHCS grant 823. D. L. B. was supported by the University of Zurich Clinical Research Priority Program Viral Infectious Diseases. R. D. K. was supported by the SNSF (grant BSSGI0_155851).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The SHCS has been approved by the ethics committee of the participating institutions (Kantonale Ethikkommission Bern, Ethikkommission des Kantons St. Gallen, Comite departemental d ethique des specialites medicales et de medicine communataire et de premier recours, Hopitaux Cantonale de Geneve, Kantonale Ethikkommission Zuerich, Repubblica e Cantone Ticino-Comitato Ethico Cantonale, Commission cantonale dêtique de la recherche sur l'être humain, Canton de Vaud, Lausanne, Ethikkommission beider Basel for the SHCS and Kantonale Ethikkommission Zuerich for the ZPHI). Written informed consent had been obtained from all participants. All methods were carried out in accordance with Swiss federal guidelines and regulations.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The individual level datasets generated or analyzed during the current study do not fulfill the requirements for open data access: 1) The SHCS informed consent states that sharing data outside the SHCS network is only permitted for specific studies on HIV infection and its complications, and to researchers who have signed an agreement detailing the use of the data and biological samples; and 2) the data is too dense and comprehensive to preserve patient privacy in persons living with HIV. According to the Swiss law, data cannot be shared if data subjects have not agreed or data is too sensitive to share. Investigators with a request for selected data should send a proposal to the respective SHCS address (www.shcs.ch/contact). The provision of data will be considered by the Scientific Board of the SHCS and the study team and is subject to Swiss legal and ethical regulations, and is outlined in a material and data transfer agreement.
